SCHEMBL26508282

SCHEMBL26508282

Cc1ccc2[nH]cc(CCN3CC(C)C3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 8/20 0.57
HTR2A P28223 4/20 0.57
CDK4 P11802 1/20 0.55
CCND1 P24385 1/20 0.55
HTR1B P28222 7/20 0.52
MPO P05164 2/20 0.51
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
DRD2 P14416 1/20 0.48
ADRA2B P18089 1/20 0.48
ADRA2C P18825 1/20 0.48
HTR2C P28335 1/20 0.48
HTR1E P28566 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26508275 0.87 HTR1D (0.55) HTR1DHTR2ACDK4CCND1HTR1B
SCHEMBL26508293 0.83 HTR2A (0.70) HTR1DHTR2ACDK4CCND1HTR1B
SCHEMBL8506914 0.83 HTR1D (0.71) HTR1DHTR2ACDK4CCND1HTR1B
SCHEMBL26508875 0.83 HTR2A (0.73) HTR1DHTR2AHTR1BMAPTMTNR1A
SCHEMBL26508256 0.82 HTR2A (0.67) HTR1DHTR2AHTR1BMPOMEN1
SCHEMBL26508279 0.82 HTR1D (0.55) HTR1DHTR2ACDK4CCND1HTR1B
SCHEMBL26508280 0.81 HTR1D (0.57) HTR1DHTR2ACDK4CCND1HTR1B
SCHEMBL26508281 0.79 HTR1D (0.56) HTR1DHTR2ACDK4CCND1HTR1B
Hydrochloric Acid SCHEMBL10566310 0.78 HTR1D (0.56) HTR1DHTR2ACDK4CCND1HTR1B
Hydrochloric Acid SCHEMBL10566305 0.78 HTR1D (0.56) HTR1DHTR2ACDK4CCND1HTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322735-A1 AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322735-A1 AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS TPH2, TPH1, HTR2A HTR1D 15/4885HTR2A 3/4885CDK4 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.